
Nerandomilast reduces FVC decline, has ‘manageable’ adverse events in IPF at 52 weeks
Add topic to email alerts Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Key takeaways: Two differing nerandomilast doses were …